Communiqués Luye Pharma Group Ltd.

Actions

2186

BMG570071099

Temps Différé Hong Kong S.E. Autres places de cotation 07:09:32 16/07/2024			Varia. 5j.	Varia. 1 janv.
2,77 ^HKD	-1,77 %		-1,42 %	-25,74 %

04/07	Le régulateur chinois approuve la commercialisation du nouveau médicament de Luye Pharma Group	MT
04/07	Luye Pharma Group Ltd. annonce l'approbation du nouveau produit analgésique Mimeixin (comprimés de chlorhydrate d'oxycodone et de chlorhydrate de naloxone à libération prolongée) pour sa commercialisation en Chine	CI

Communiqués

Débloquez toutes les actualités : Soyez le premier informé et réagissez avant les marchés !

Inscription 100% Gratuite

Luye Pharma : Analgesic Drug Mimeixin (Oxycodone Hydrochloride and Naloxone Hydrochloride Sustained-Release Tablets) Approved for ...	04/07	PU
Luye Pharma : Manufacturing Facility for Paliperidone Palmitate Extended-release Injectable Suspension (LY03010) Passes FDA’s PAI ...	28/06	PU
Luye Pharma : Jinyouping (Rotigotine Microspheres for Injection) Approved for Marketing in China	20/06	PU
Luye Pharma : Meibirui (Paliperidone Palmitate Injection) Approved for Marketing in China for Treating Schizophrenia	11/06	PU
Luye Pharma : Announces the Approval of Lurbinectedin for the Treatment of Relapsed Small Cell Lung Cancer in Hong Kong	12/12	PU
PharmaMar receives approval of Zepzelca for the treatment of metastatic small cell lung cancer in Macau, China	05/12	AQ
Luye Pharma : Rivastigmine Twice Weekly Transdermal Patch Approved in China for the Treatment of Alzheimer's Disease	01/11	PU
Luye Pharma : The World’s Only Goserelin Microsphere Formulation (Baituowei) Approved in China for the New Indication of Breast Cancer	08/09/23	PU
Luye Pharma : Announces 2023 Half Year Results	30/08/23	PU
Luye Pharma : China’s NMPA Accepts and Grants Priority Review Designation to the New Drug Application for Luye Pharma’s Rotigotine Extended-Release ...	02/08/23	PU
Luye Pharma : Patient Enrollment Completed for a Phase 2 Clinical Study of Luye Pharma’s Class 1 Analgesic Drug Candidate LY03014	07/07/23	PU
Bone Metastases Pipeline, Clinical Trials, and Key Companies\|Companies - Mabwell (Shanghai) Bioscience Co., Ltd., AlaMab Therapeutics, Qilu Pharmaceutical Co., Ltd., Exelixis, Shanghai JMT-Bio Inc.	13/06/23	AQ
PharmaMar and Luye Pharma announce the acceptance of the registration application for the approval of lurbinectedin in China	07/06/23	AQ
Luye Pharma : and Duopharma Reach Strategic Partnership to Expand Accessibility of Cholesterol Management Products in Malaysia	05/04/23	PU
Luye Pharma : Receives Clinical Trial Approval in Europe for Its Innovative Formulation Paliperidone Palmitate Long-acting Injection ...	24/02/23	PU
Luye Pharma : 3-month Long-acting Goserelin Microspheres Approved for Clinical Trials in China	31/01/23	PU
Luye Pharma : Innovative Anti-Cancer Therapy Lurbinectedin to Benefit “Named Patients” in Hong Kong	09/01/23	PU
Luye Pharma : Boan Biotech’s First Investigational ADC, BA1301 for Injection, Approved for Clinical Trials in China	09/01/23	PU
Luye Pharma : Boan Biotech Officially Listed on the Main Board of SEHK Accelerating to Become a Leading Global Biopharmaceutical Company	30/12/22	PU
Luye Pharma : World’s First Denosumab Biosimilar Boyoubei® Launched in China	10/12/22	PU

Aucun résultat pour cette recherche

Toute l'actualité Reco analystes Faits marquants Insiders Transcripts Communiqués Publications officielles Autres langues Idées de trading Articles Zonebourse Analyses Zonebourse

Communiqués Luye Pharma Group Ltd.

Actions

2186

BMG570071099

Communiqués

Filtres